GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » Return-on-Tangible-Equity

Elanco Animal Health (Elanco Animal Health) Return-on-Tangible-Equity : 0.00% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Elanco Animal Health's annualized net income for the quarter that ended in Dec. 2023 was $-564 Mil. Elanco Animal Health's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-3,304 Mil. Therefore, Elanco Animal Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Elanco Animal Health's Return-on-Tangible-Equity or its related term are showing as below:

During the past 9 years, Elanco Animal Health's highest Return-on-Tangible-Equity was 9.24%. The lowest was -15.66%. And the median was -2.62%.

ELAN's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.73
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Elanco Animal Health Return-on-Tangible-Equity Historical Data

The historical data trend for Elanco Animal Health's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health Return-on-Tangible-Equity Chart

Elanco Animal Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Negative Tangible Equity - - - -

Elanco Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - Negative Tangible Equity - - -

Competitive Comparison of Elanco Animal Health's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanco Animal Health's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Elanco Animal Health's Return-on-Tangible-Equity falls into.



Elanco Animal Health Return-on-Tangible-Equity Calculation

Elanco Animal Health's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-1231/( (-3546+-3365 )/ 2 )
=-1231/-3455.5
=N/A %

Elanco Animal Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-564/( (-3243+-3365)/ 2 )
=-564/-3304
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Elanco Animal Health  (NYSE:ELAN) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Elanco Animal Health Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanco Animal Health (Elanco Animal Health) Business Description

Traded in Other Exchanges
Address
2500 Innovation Way, Greenfield, IN, USA, 46140
Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Executives
Grace Mcardle officer: EVP, MANUFACTURING AND QUALITY 2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington officer: See remarks C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
R David Hoover director C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Jeffrey N Simmons director, officer: Pres., Chief Executive Officer 2500 INNOVATION WAY, GREENFIELD IN 46140
John P Bilbrey director
Rajeev A. Modi officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen director C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Michael J Harrington director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Brabander Ellen De officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger officer: Ex VP, Gen Counsel & Corp Sec C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia director 11690 N.W. 105TH STREET, MIAMI FL 33178
William F Doyle director
Uncas Gp Llc director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019